Floatz logo

Erwinia L-Asparaginase

Acute Lymphoblastic Leukemia, Pediatric

Dana-Farber Cancer InstitutePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

70 Active assets in the Acute Lymphoblastic Leukemia, Pediatric cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Erwinia L-Asparaginase is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
65 / 100
View asset →
lymphoblastic lymphomaDormant
B
Indicative ·
59 / 100
View asset →
mixed phenotype acute leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →